Cart
sales@molnova.com
OUL232
CAS No. 943119-42-4
OUL232( —— )
Catalog No. M36535 CAS No. 943119-42-4
OUL232 is a potent single ARTs PARP7, PARP10, PARP11, PARP12, PARP14 and PARP15 inhibitor for cancer and tumour research.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 93 | In Stock |
|
| 5MG | 140 | In Stock |
|
| 10MG | 211 | In Stock |
|
| 25MG | 361 | In Stock |
|
| 50MG | 544 | In Stock |
|
| 100MG | 771 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameOUL232
-
NoteResearch use only, not for human use.
-
Brief DescriptionOUL232 is a potent single ARTs PARP7, PARP10, PARP11, PARP12, PARP14 and PARP15 inhibitor for cancer and tumour research.
-
DescriptionOUL232 is a potent inhibitor of mono-ARTs PARP7, PARP10, PARP11, PARP12, PARP14, and PARP15. OUL232 is the most potent PARP10 inhibitor described to date (IC50=7.8 nM), as well as the first PARP12 inhibitor ever reported.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetPARP
-
RecptorPARP
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number943119-42-4
-
Formula Weight250.28
-
Molecular FormulaC10H10N4O2S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (199.78 mM; ultrasonic and warming and adjust pH to 2 with 1M HCl and heat to 80°C)
-
SMILESN=1N=C(N)N2C1SC=3C(OC)=CC=C(OC)C32
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Murthy S, et al. [1,2,4]Triazolo[3,4-b]benzothiazole Scaffold as Versatile Nicotinamide Mimic Allowing Nanomolar Inhibition of Different PARP Enzymes. J Med Chem. 2023 Jan 4. ?
molnova catalog
related products
-
KSQ-4279
KSQ-4279 (USP1-IN-1) is an inhibitor of USP1 and PARP, exhibiting anticancer activity. It is utilized in the study of non-small cell lung cancer, osteosarcoma, ovarian, breast, glioblastoma, bladder, uterine, and pancreatic cancers.
-
TIQ-A
TIQ-A is a PARP1 inhibitor which involved in DNA single-strand break repair via the base excision repair pathway. PARP1 is triggered by DNA damage and its excessive activation has been proposed as a causative factor in many pathological conditions including ischemia and reperfusion injury, asthma-related inflammation, and atherogenesis.
-
Senaparib
Senaparib is a novel highly potent and selective oral PARP1/2 inhibitor with strong antitumor activity.
